CRISPR Therapeutics AG
NASDAQ:CRSP
CRISPR Therapeutics AG
NASDAQ:CRSP
Price:
31.27
USD
-3.43%
Market Closed
Market Cap:
2.7B
USD
P/FCFE
Price to FCFE
Price to FCFE
-18.5
Current
-12.3
Median
23.8
Industry
Lower
than median
Lower
than industry value
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
P/FCFE
=-18.5
Market Cap
/
2.7B USD
FCFE
-144.7m USD
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A
You don't have any saved screeners yet
